NCT05447325 Neuroimaging Approaches to Improve Prediction of Smoking Initiation and Nicotine Escalation in Young Adult ENDS Users
| NCT ID | NCT05447325 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Georgia |
| Condition | Message Exposure (Sequence: Regular Then Flavor) |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2022-07-15 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2022-07-15 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
180 young adult vapers who are not current smokers will participate in a baseline functional magnetic resonance imaging (fMRI) experiment, prospectively linked to a 1-year randomized controlled trial. Baseline fMRI tasks will probe critical neurocognitive markers with high potential to account for individual differences in nicotine use prognosis and responsiveness to anti-vaping public service announcements (PSAs). Participants will be assigned randomly to a survey-only control condition, or one of two intervention orders, Regular PSA then Flavor PSA, and Flavor PSA then Regular PSA (n=60 each) in a 1-year counterbalanced crossover design. Every week intervention groups will receive anti-vaping PSAs either do not specifically address harms associated with vaping flavors (regular PSAs) or PSAs with a theme focusing on the harms of flavored vape products (flavor PSAs). Participants of the intervention groups will switch PSA exposure condition after 6 months. Their evaluations of the PSAs will be assessed with brief weekly online surveys. The links to the weekly online surveys will be sent via e-mail and text which allow them to access the surveys using any device with an internet browser. During the survey, the PSA of that week will first be displayed to PSA groups (n=120), followed by a query to provide message evaluation. Afterward, the survey questions will also assess their e-cigarette, cigarette, other tobacco use, and nicotine dependence, during the past week. The control group (n=60) will complete the surveys without viewing PSAs. In-person assessments at 3, 6, 9, and 12 months will biochemically confirm nicotine exposure.
Eligibility Criteria
Inclusion Criteria: * used e-cigarettes or other vaping devices at least 3 days during the past 30 days * did not smoke a cigarette, even one or two puffs, during the past 30 days * Magnetic resonance imaging (MRI) compatible and safe Exclusion Criteria: * used e-cigarettes or other vaping devices for less than 3 days during the past 30 days * any use of cigarettes during the past 30 days * history of a major neurological, psychiatric, or medical disorder * MRI contraindications
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05447325 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 29 Years, studying Message Exposure (Sequence: Regular Then Flavor). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05447325 currently recruiting?
Yes, NCT05447325 is actively recruiting participants. Contact the research team at jiaying.liu@uga.edu for enrollment information.
Where is the NCT05447325 trial being conducted?
This trial is being conducted at Athens, United States.
Who is sponsoring the NCT05447325 clinical trial?
NCT05447325 is sponsored by University of Georgia. The trial plans to enroll 180 participants.